# US 12,006,305 B2 · Salts of obicetrapib and processes for their manufacture and intermediates thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,006,305 B2 - Document ID: US12006305B2 - Status: Granted - Kind: B2 - Application number: 18/346,342 - Filed: 2023-07-03 - Published: 2024-01-11 - Granted: 2024-06-11 - Earliest claimed: 2022-07-05 - Assignees: NewAmsterdam Pharma B.V. - Applicants: NewAmsterdam Pharma B.V. - Inventors: Sheng Cui; Andreas René Rötheli; Christopher J. Borths; Muneki Kishida - Web page: https://patentgrep.com/patent/US12006305B2 ## CPC - C07D 401/12: linked by a chain containing hetero atoms as chain links - A61K 31/33: Heterocyclic compounds - A61P 9/00: Drugs for disorders of the cardiovascular system - C07B 2200/13: Crystalline forms, e.g. polymorphs - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F) ## Abstract Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obicetrapib, and salts thereof are also provided, including obicetrapib HCl and a mesylate salt for the use in the synthesis of obicetrapib and amorphous obicetrapib hemicalcium. ## Claims ### Claim 1 Amorphous obicetrapib hemicalcium. ### Claim 2 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having an x-ray powder diffraction pattern comprising one or more peaks at about 3.4° 2θ, about 7.0° 2θ, and about 9.2° 2θ. ### Claim 3 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having a glass transition temperature at a value between about 109° C. and about 112° C., when measured by modulated differential scanning calorimetry in a sample pan with an opening. ### Claim 4 (depends on 2) The amorphous obicetrapib hemicalcium of claim 2, having a glass transition temperature at a value between about 109° C. and about 112° ° C., when measured by modulated differential scanning calorimetry in a sample pan with an opening. ### Claim 5 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having a solid-state 13C-NMR spectrum substantially the same as that of FIG. 17. ### Claim 6 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having a solid-state 13C-NMR spectrum where no peak is present at either about 22.1 ppm or about 29.5 ppm. ### Claim 7 (depends on 2) The amorphous obicetrapib hemicalcium of claim 2, having a solid-state 13C-NMR spectrum substantially the same as that of FIG. 17. ### Claim 8 (depends on 2) The amorphous obicetrapib hemicalcium of claim 2, having a solid-state 13C-NMR spectrum where no peak is present at either about 22.1 ppm or about 29.5 ppm. ### Claim 9 (depends on 3) The amorphous obicetrapib hemicalcium of claim 3, having a solid-state 13C-NMR spectrum substantially the same as that of FIG. 17. ### Claim 10 (depends on 3) The amorphous obicetrapib hemicalcium of claim 3, having a solid-state 13C-NMR spectrum where no peak is present at either about 22.1 ppm or about 29.5 ppm. ### Claim 11 (depends on 4) The amorphous obicetrapib hemicalcium of claim 4, having a solid-state 13C-NMR spectrum substantially the same as that of FIG. 17. ### Claim 12 (depends on 4) The amorphous obicetrapib hemicalcium of claim 4, having a solid-state 13C-NMR spectrum where no peak is present at either about 22.1 ppm or about 29.5 ppm. ### Claim 13 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having a d90 particle size distribution of between 6 and 15 microns. ### Claim 14 (depends on 2) The amorphous obicetrapib hemicalcium of claim 2, having a d90 particle size distribution of between 6 and 15 microns. ### Claim 15 (depends on 3) The amorphous obicetrapib hemicalcium of claim 3, having a d90 particle size distribution of between 6 and 15 microns. ### Claim 16 (depends on 4) The amorphous obicetrapib hemicalcium of claim 4, having a d90 particle size distribution of between 6 and 15 microns. ### Claim 17 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having a chemical purity of at least 99.0%. ### Claim 18 (depends on 2) The amorphous obicetrapib hemicalcium of claim 2, having a chemical purity of at least 99.0%. ### Claim 19 (depends on 17) The amorphous obicetrapib hemicalcium of claim 17, having a chemical purity of at least 99.9%. ### Claim 20 (depends on 18) The amorphous obicetrapib hemicalcium of claim 18, having a chemical purity of at least 99.9%. ### Claim 21 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having an x-ray powder diffraction pattern substantially the same as that of FIG. 3. ### Claim 22 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, wherein the amorphous obicetrapib calcium does not birefringe. ### Claim 23 (depends on 2) The amorphous obicetrapib hemicalcium of claim 2, wherein the amorphous obicetrapib calcium does not birefringe. ### Claim 24 (depends on 3) The amorphous obicetrapib hemicalcium of claim 3, wherein the amorphous obicetrapib calcium does not birefringe. ### Claim 25 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, wherein the obicetrapib hemicalcium is milled. ### Claim 26 (depends on 1) The amorphous obicetrapib hemicalcium of claim 1, having a water content of less than about 4%. ### Claim 27 (depends on 26) The amorphous obicetrapib hemicalcium of claim 26, having a water content of between about 0.5% and about 1.5%.